The role of senescence in the development of osteoporosis and osteoarthritis
Authors:
Kroupová Květa 1; Palička Vladimír 2
Authors‘ workplace:
Ústav klinické biochemie a diagnostiky FN Hradec Králové
1; Osteocentrum, Ústav klinické biochemie a diagnostiky LF UK a FN Hradec Králové
2
Published in:
Clinical Osteology 2023; 28(1-2): 19-23
Category:
Overview
The unstoppable progress in medicine results in a dramatically increasing increase in average life expectancy, but a person does not always live his life in health as defined in 2021 by the so-called Tripartite (World healthy organization – WHO, Food and Agriculture Organization of the United Nations – FAO UN, World Organisation for Animal Health, until 2003 Office International des Epizooties – OIE) [1,2]. As life expectancy increases, the number of people suffering from chronic diseases increases exponentially. Chronic diseases associated with old age also include musculoskeletal diseases, and one of the representative diagnoses is osteoporosis and osteoarthritis [2,3,4]. Between 2010 and 2019, the number of osteoporotic patients worldwide increased by 5 million, i.e. to 32 million people who are at risk of an osteoporotic fracture, which is usually the first symptom of this “silent” disease. In the Czech Republic in 2019, 572 thousand people suffered from osteoporosis, while approximately 80 % of them remain untreated (treatment gap). The number of patients with a low-traumatic fracture increased from 72,195 to 91,349 between 2010 and 2019. The most prominent subset are vertebral fractures and fractures of proximal femur, which have a 10 to 30 % risk of death within 12 months of their occurrence [2,4]. Osteoarthritis (OA) is one of the most common joint diseases. The prevalence is not precisely mapped, according to some world and Czech statistics, 40 % of people over 60 and even 80 % of people over 65 suffer from osteoarthritis [5,6]. The most common localization of OA is the knee joints, hip joints, small joints of the hands and joints on the spine, where not only the articular hyaline cartilage is affected, but also the synovium, joint capsule, tendon and ligament attachments, muscle attachments and subchondral bone. In younger people, it is mostly a posttraumatic condition, in older people the influence of genetic, biomechanical, endocrinological, inflammatory agents and factors associated with cartilage aging is assumed [5,6,7]. Especially in the last decade, there is growing evidence linking both of these diseases to cell senescence [7,8].
Keywords:
osteoarthritis – Senescence – osteoporosis
Sources
1. WHO. Tripartite and UNEP support OHHLEP's definition of "One Health". 2021. Dostupné z WWW: <https://www.who.int/news/item/01–12–2021-tripartite-and-unep-support-ohhlep-s-definition-of-one--health>. [5. 3. 2023]
2. Harvey NCW, McCloskey EV, Mitchell PJ et al. Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures Osteoporos Int 2017; 28(5): 1507–1529. Dostupné z DOI: <https://doi:10.1007/s00198–016–3894-y>.
3. Khosla S, Cauley JA, Compston J et al. Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward. J Bone Miner Res 2017; 32(3): 424–430. Dostupné z DOI: <https://doi: 10.1002/jbmr.3074>. PMID: 28099754.
4. Kanis JA, Cooper C, Rizzoli R, Reginster JY. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos Int 2019; 30(1): 3–44. Dostupné z DOI: <https://doi:10.1007/s00198–018–4704–5>. [Corrections in: Osteoporos Int 2020; 31(1): 209 and Osteoporos Int 2020; 31(4): 801].
5. Pavelka K. Může ovlivnění subchondrální kosti zpomalovat progresi osteoartrózy? Clin Osteol 2019; 24(2): 62–67.
6. Jeon OH, David N, Campisi J et al. Senescent cells and osteoarthritis: a painful c onnection. J Clin I nvest 2 018; 128(4): 1229–1237. Dostupné z DOI: <https://doi:10.1172/JCI95147>.
7. Pignolo RJ, Law SF, Chandra A. Bone Aging, Cellular Senescence, and Osteoporosis. JBMR Plus 2021; 5(4):e10488. Dostupné z DOI: https://doi: 10.1002/jbm4.10488. PMID: 33869998. PMCID: PMC8046105.
8. Feng X. Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and Disease. Curr Chem Biol 2009; 3(2):189–196. Dostupné z DOI: <https://doi: 10.2174/187231309788166398>. PMID: 20161446. PMCID: PMC2790195.
9. Rosa J, Palička V, Býma S. Osteoporóza. Doporučené diagnostické a léčebné postupy pro praktické lékaře. Novelizace 2018. Společnost všeobecného lékařství ČLS JEP: Praha 2018. ISBN 978–80–86998–98–5.
10. Tripathi U, Misra A, Tchkonia T et al. Impact of Senescent Cell Subtypes on Tissue Dysfunction and Repair: Importance and Research Questions. Mech Ageing Dev 2021; 198:111548. Dostupné z DOI: <https://doi: 10.1016/j.mad.2021.111548>. PMID: 34352325. PMCID: PMC8373827.
11. López-Otín C, Blasco MA, Partridge L et al. The hallmarks of aging. Cell 2013; 153(6): 1194–1217. Dostupné z DOI: <https://doi: 10.1016/j.cell.2013.05.039>. PMID: 23746838. PMCID: PMC3836174.
12. Farr JN, Khosla S. Cellular senescence in bone. Bone 2019; 121: 121–133. Dostupné z DOI: <https://doi: 10.1016/j.bone.2019.01.015>. PMID: 30659978. PMCID: PMC6485943.
13. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25: 585–621.
14. Chaib S, Tchkonia T, Kirkland JL. Cellular senescence and senolytics: the path to the clinic. Nat Med 2022; 28: 1556–1568. Dostupné z DOI: <https://doi.org/10.1038/s41591–022–01923-y>.
15. Lam B, Roudier E. Considering the Role of Murine Double Minute 2 in the Cardiovascular System? Front Cell Dev Biol 2019; 7:320. Dostupné z DOI: <https://doi: 10.3389/fcell.2019.00320>. PMID: 31921839; PMCID: PMC6916148.
16. Khosla S, Farr JN, Monroe DG. Cellular senescence and the skeleton: pathophysiology and therapeutic implications. J Clin Invest 2022; 1 32(3): e 154888. D ostupné z D OI: < https://doi.org/10.1172/JCI154888>.
17. Chandra A, Lagnado AB, Farr JN et al. Targeted Reduction of Senescent Cell Burden Alleviates Focal Radiotherapy-Related Bone Loss. J Bone Miner Res 2020; 35(6): 1119–1131. Dostupné z DOI: <https://doi: 10.1002/jbmr.3978>. PMID: 32023351. PMCID: PMC7357625
18. Masutomi K, Possemato R, Wong JM et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A 2005; 102(23): 8222–8227. Dostupné z DOI: <https://doi: 10.1073/pnas.0503095102>. PMID: 15928077. PMCID: PMC1149439.
19. Schmitt CA, Wang B, Demaria M. Senescence and cancer – role and therapeutic opportunities. Nat Rev Clin Oncol 2022; 19: 619–636. Dostupné z DOI: <https://doi.org/10.1038/s41571–022–00668–4>.
20. Weilner S, Grillari-Voglauer R, Redl H et al. The role of microRNAs in cellular senescence and age-related conditions of cartilage and bone. Acta Orthop 2015; 86(1): 92–99. Dostupné z DOI: <https://doi:10.3109/17453674.2014.957079>.
21. Farr JN, Fraser DG, Wang H et al. Identification of Senescent Cells in the Bone Microenvironment. J Bone Miner Res 2016; 31(11): 1920–1929. Dostupné z DOI: <https://doi: 10.1002/jbmr.2892>. PMID: 27341653. PMCID: PMC5289710.
22. Wang T, Huang S, He C. Senescent cells: A therapeutic target for osteoporosis. Cell Prolif 2022; 55(12): e13323. Dostupné z DOI: <https://doi: 10.1111/cpr.13323>. PMID: 35986568. PMCID: PMC9715365.
23. Coryell PR, Diekman BO, Loeser RF. Mechanisms and therapeutic implications of cellular senescence in osteoarthritis. Nat Rev Rheumatol 2021; 17(1): 47–57. Dostupné z DOI: <https://doi: 10.1038/s41584–020–00533–7>. PMID: 33208917. PMCID: PMC8035495.
24. A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee. Dostupné z WWW: <https://clinicaltrials.gov/ct2/show/NCT03513016>.
25. Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans. Dostupné z WWW: <https://clinicaltrials.gov/ct2/show/study/NCT04313634>.
26. Hickson LJ, Langhi Prata LGP, Bobart SA et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. E BioMedicine 2 019; 4 7: 4 46–456. D ostupné z DOI: < https://doi:10.1016/j.ebiom.2019.08.069>. Erratum in: EBioMedicine 2020; 52:102595. PMID: 31542391. PMCID: PMC6796530.
Labels
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology OsteologyArticle was published in
Clinical Osteology
2023 Issue 1-2
Most read in this issue
- Exostosis of proximal femur – benign tumor, “malign” location: a case report
- Pregnancy associated osteoporosis
- Reflection on the causes of senile osteoporosis
- Jak a čím žije česká klinická osteologie v dnešní době